Pathogenesis Based Therapies
At TBT we treat the cause, not the symptom, by developing targeted therapeutic solutions geared at the underlying pathology. We are a clinical stage dermatology company dedicated to developing and commercializing products to benefit the lives of patients afflicted by psoriasis, orphan diseases, and other inflammatory skin conditions. We do this by taking advantage of recent discoveries about skin and exploiting them by re-purposing oral and intravenous generic and off-patent compounds for topical use, improving outcomes and patient satisfaction while reducing costs.
Inflammatory skin conditions
WHAT WE DO
THE WORLD IS READY FOR TBT
Tens of millions of Americans are impacted by debilitating skin disorders each year – and over 7.5 million have chronic psoriasis. Inflammatory skin conditions impact individuals and families alike, exacting a physical, emotional, and economic toll, often times preventing those affected from working, socializing, and generally enjoying the simple pleasures of life that most Americans take for granted. What’s even more daunting is that researchers believe the future trend of new cases to continue unabated. The fact is that the number of people affected by debilitating skin ailments is growing much quicker than science is offering constructive healthy solutions.
The current menu of drugs on the market are too expensive, often don’t hit the target, and are rife with potentially deadly side effects because they suppress the immune system of the patient. No gallows humor intended, but it’s like amputating a patient’s hand to treat a hang-nail on their little finger.
There is a a better way.
TBT Pharma is committed to disrupt the status quo and turn upside down the current mind-set of how to treat problematic skin conditions with breakthrough topical applications for patients suffering from psoriasis and other skin conditions.